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determine tetanus immunity in patients with a
wound in french emergency departments
Dieynaba S N’Diaye1,2,3*, Michaël Schwarzinger1,2, Dorothée Obach1,2, Julien Poissy4, Sophie Matheron5,
Enrique Casalino6 and Yazdan Yazdanpanah1,2,5Abstract
Background: Tétanos Quick Stick® (TQS) is a test for tetanus immunity screening for wounded patients in
emergency departments (EDs), but represents additional costs compared with a medical interview on vaccination
history. The study objective was to assess the effectiveness and cost of the TQS in French EDs.
Methods: We performed a model-based analysis that simulates screening of tetanus immunity and risk of tetanus
based on prophylaxis administration. Strategies compared were: i) diagnosis of tetanus immunity by “TQS”; ii) “Medical
Interview” (current practice). The study population was 1,658,000 French adults seeking ED care for a wound in 2012.
Model parameters were estimated based on French national surveillance data, and published literature. Outcome
measures were number of tetanus cases, life years gained and costs (2012 €) from a societal perspective.
Results: Use of TQS had negligible impact on health outcomes (0.02 tetanus cases/year in France vs. 0.41 for
“Medical Interview”), but resulted in a decrease in annual costs of €2,203,000 (−42%). Base case and sub-group
analysis showed that with the same effectiveness, the average cost per patient was: €13 with “Medical Interview”
vs. €11.7 with TQS for the overall cohort; €28.9 with “Medical Interview” vs. €21 with “TQS” for tetanus-prone
wounds; €15 with “Medical Interview” vs. €14.1 with “TQS” for patients aged ≥65 years; and €6.2 with “Medical
Interview” vs. €7.8 with “TQS” for non-tetanus-prone wounds.
Conclusions: Use of TQS is as effective and less costly than “Medical Interview” when applied in ED to
wounded patients with tetanus-prone wounds or aged ≥65 years. However, it is more expensive in patients with
non-tetanus-prone wounds.
Keywords: Tetanus immunity, Diagnostic tests, Cost-effectiveness, Emergency departmentBackground
In high-income countries, thanks to systematic immuni-
zation campaigns and prophylaxis strategies, tetanus is a
rare disease. In France, the annual incidence rate of
tetanus for the period 2000–2012 is estimated to be
0.27 cases per million inhabitants [1].
Alongside universal vaccination, unscheduled tetanus
prophylaxis is administered to patients with a wound de-
pending on its severity and the patient’s vaccination status* Correspondence: ndiayedieynaba@hotmail.fr
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unless otherwise stated.(Table 1) [2,3]. Currently, in emergency departments
(EDs), healthcare workers assess tetanus immunization
status by asking for the patient’s vaccination card or
through a medical interview retracing the patient’s vaccin-
ation history. However, patients rarely bring their vaccin-
ation cards, and multiple studies have shown that medical
interviews lack accuracy [4-8]. For example, Colombet
et al. reported that the sensitivity and specificity of this
practice was 62% and 79%, respectively [5].
Immunization status, as defined by serum tetanus anti-
toxin level, can now be more accurately determined
through rapid testing using immunochromatographic
methods. Colombet et al. recently showed that one of
these tests, the Tétanos Quick Stick® TQS) (TQS; Ingen,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Guidelines for tetanus prophylaxis for wound management in French EDs
Type of wound Vaccination history
Complete primary vaccination No or unknown complete primary vaccination
Boostera updatedb Booster not updated
Non-tetanus-prone wound Nothing Booster Booster (proposal to update the primary vaccination)d
Tetanus-prone woundc Nothing Booster + TIG Booster + TIG (proposal to update the primary vaccination)
ED: Emergency department; TIG: Human tetanus immunoglobulins;
aTetanus-toxoid vaccine.
bAccording to the French vaccination schedule; i.e. having received a tetanus-toxoid injection during the last 20 years for those <65 years of ageand during the
last 10 years of those aged ≥65 years.
cSuch as (but not limited to) wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles, crushing,
burns, and frostbite.
dPrimary vaccination update: administration of two other boosters at a one-month interval, usually by a general practitioner.
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cificity than medical interview for immunization status
determination [5]. However, such tests are associated with
higher costs than the medical interview. The estimated
unit cost of a test is €4.7 [9].
The objective of this study was, in the current context
of implemented guidelines, to assess using a model-based
analysis, in French patients presenting to the ED with
wounds, the effectiveness, costs and cost-effectiveness of
rapid tests and in particular TQS for tetanus immunization
status determination vs. current practice based on the
medical interview.
Methods
Analytic overview
We developed a decision-tree model that simulates
the trajectory of a cohort of adult patients seeking care
in EDs for a wound during the year 2012 in France.
Each patient’s trajectory incorporates wound type, tet-
anus immunization status diagnosis, administration of
unscheduled tetanus prophylaxis according to immuni-
zation status, and the risk for tetanus and related survival
with or without sequelae (Figure 1). Several parameters
used in the model (immunization status, unscheduled vac-
cination guidelines, tetanus incidence) vary with age; we
therefore stratified our adult study population into two age
groups: 18–64 years old and ≥65 years. Since tetanus inci-
dence and prophylaxis guidelines differ according to the
type of wound, we also stratified the study population into
patients with and without tetanus-prone wounds. The
model was developed and analyzed using TreeAge Pro
2012 (TreeAge Software, Inc., Williamstown, MA).
Strategies
Two strategies to diagnose the tetanus immunization sta-
tus were compared and applied each on the entire hypo-
thetical cohort of patients considered in the analysis.
(i) “Medical Interview” strategy (current practice)
The “Medical Interview” is illustrated in Figure 1. Patients
were first asked whether they had their vaccination card.If they did, this card showed whether their last booster
was up to date or not. If they did not, they are asked about
their tetanus vaccination history in a medical interview. If
they reported “No or unknown complete primary vaccin-
ation”, based on French guidelines, they were given a
booster and a human tetanus immunoglobulin (TIG) in-
jection in the case of tetanus-prone wounds, and only a
booster in the case of no tetanus-prone wounds. If the pa-
tients asserted having received a “Complete primary vac-
cination”, they were asked if their boosters were up to
date. Those replying yes received no prophylaxis; those
replying no received a booster and a TIG injection in the
case of tetanus-prone wounds and only a booster in the
case of no tetanus-prone wounds.
(ii) “TQS” strategy
The “TQS” strategy is illustrated in Figure 1. As in the
“Medical Interview” strategy, patients were first asked
about their vaccination card. Patients without a vaccin-
ation card were systematically screened with a TQS. A
positive test classified the patient as immune (i.e. with
serum anti-tetanus antibody above 0.1 IU/mL of blood)
[2]. Immune patients received no prophylaxis. A negative
test classified the patient as non-immune (i.e. serum anti-
tetanus antibody under the protective threshold). Non-
immune patients received unscheduled tetanus prophylaxis
like patients in the “Medical Interview” strategy.
Outcomes
Based on this model, we estimated for each strategy the
proportion of patients correctly and incorrectly diag-
nosed, the number of tetanus cases per year, and the co-
hort’s life expectancy. We also assessed overall costs in
order to calculate the incremental cost-effectiveness ratio
(ICER) of the “TQS” strategy compared with current prac-
tice [10].
Since wound type determines ED care and has an impact
on tetanus risk, we conducted a sub-analysis on tetanus-
prone and non-tetanus-prone wounds. Because patients
aged ≥65 years are less immune against tetanus, we also
conducted a specific analysis in this population [11].
Figure 1 Decision-tree model: strategies compared and sub-trees. TQS: Tétanos Quick Stick; TP: True Positive; FP: False Negative; TN: True
Negative; FN: False Negative (A) True Positive sub-tree; (B) True Negative sub-tree; (C) False Positive sub-tree; (D) False Negative sub-tree;
*For non-tetanus-prone wound; # For tetanus-prone wound.
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Key simplifying assumptions in this model included the
following:
1. If patients came to the ED with a vaccination card, the
health care professional considered the card as written
evidence of the patient’s true immunization status.
2. We considered that patients who were not immune
and who received appropriate tetanus prophylaxis
would not develop tetanus.
Data and sources
Model input variable parameters were mainly estimated
using national observational data and, when not avail-
able, through an extensive review of the international
literature (Table 2).
Our study population was an annual cohort of wounded
adults seeking care in an ED. These correspond to 13% of
the 12.7 million adults annually seeking care in French
EDs, 16.6% of whom were aged ≥65 years, and 70.3%
were male [5,8,12,13]. Children were not considered
in this analysis because data on TQS and medicalinterview performance are lacking in this population.
Based on Colombet et al. data, 31% of the patients had a
tetanus-prone-wound [5].
The true immunization rate of patients aged 18–64
years was estimated to be 94.6% based on ELISA test re-
sults in the Colombet et al. study (see Additional file 1:
Technichal Appendix) [5]. Seroprevalence in patients aged
≥65 years was estimated as 76.6% using data from a study
of vaccination coverage in this population by the Institut
de Veille Sanitaire, which is the French Institute for Public
Health Surveillance.
The probability of having a vaccination card when com-
ing to the ED was estimated as 12% [5]. The performances
of the two screening strategies in defining the
immunization status of patients were estimated using the
findings of Colombet et al. [5]. The sensitivity and specifi-
city of TQS testing of blood samples in ED conditions were
estimated to be 69% and 98%, respectively [5]. Based on
the same data, medical interview sensitivity and specificity
were estimated as 62% and 79%, respectively.
Tetanus incidence was estimated based on age, the
type of wound, and the administration or not of
Table 2 Model parameters base case values and ranges used in the sensitivity analyses
Parameter Base case value Min Max Source
Annual number of patients ≥18 years
coming to French EDs
12,757,000 12,223,000 13,243,000 [12]
Cohort size (wounded patients ≥18 years
coming to the French EDs)
1,658,000 1,589,000 1,722,000 Calculus based
on [13] and [12]
Pr wound│ED consultation 13.0% 10.0% 15.0% [13]
Pr tetanus-prone wound│wound 31.0% 18.1% 77.3% [5,6,14-17]
Pr highly tetanus-prone wound│wound 4.9% [6]
Pr patients ≥65 years in the cohort 16.6% 10.0% 20.0% [8,12]
Pr men in the cohort 70.3% 45.7% 75.0% [5,6,8,15,16]
Life expectancy (Pr men in the cohort ×Average men’s life expectancy
of the age group) + ((1- Pr men in the cohort)×Average
women’s life expectancy of the age group)
18 to 64 years 40.9 38.9 44.7 [18]
≥65 years 9.1 8.4 10.4
Pr vaccination card 11.9% 0.0% 19.6% [5,14,16]
Medical interview sensitivity 62.0% 38.0% 65.0% [4-8]
Medical interview specificity 79.0% 66.0% 96.0% [4-8]
TQS sensitivity 69.0% 55.0% 96.0% [4-8,19,20]
TQS specificity 98.0% 87.2% 100.0% [4-8,19,20]
Seroprevalence (≥0.1 IU/mL)
18 to 64 years 94.6% 84.0% 96.6% [5]
≥65 years 76.6% 72.2% 83.3% [21]
Pr of being up-to-date with booster shots
18 and 64 years (last booster less than
20 years ago)
71.2% 70.0% 81.0% [22]
≥65 years (last booster less than 10 years
ago)
44.0% 44.0% 77.0% [11]
Pr of booster being assessed as up-to-date (Medical interview sensitivity×Pr up-to-date
with boosters) + ((1-Medical interview specificity)
×(1-Pr up-to-date with boosters))
18 to 64 years 50.2%
≥65 years 39.0%
Pr positive TQS (TQS sensitivity×Seroprevalence) +
((1-TQS specificity)×(1-Seroprevalence))
18 and 64 years 65.7%
≥65 years 53.3%
Pr of patient reporting having
a complete primary vaccination
69.9% 71.5% 50.4% [5,15]
Medical interview PPV Pr up-to-date with boosters×Medical interview
sensitivity/((Pr up-to-date with boosters×Medical
interview sensitivity) + ((1-Pr up-to-date with
boosters)×(1-Medical interview specificity)))
18 to 64 years 88.0%
≥65 years 69.9%
Medical interview NPV (1-Pr up-to-date with boosters)×Medical interview
specificity/(((1-Pr up-to-date with boosters)
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Table 2 Model parameters base case values and ranges used in the sensitivity analyses (Continued)
×Medical interview specificity) + (Pr up-to-date
with boosters×(1-Medical interview sensitivity)))
18 to 64 years 45.7%
≥65 years 72.6%
TQS PPV Seroprevalence×TQS sensitivity/((Seroprevalence×TQS
sensitivity) + ((1-Seroprevalence)×(1-TQS specificity)))
18 to 64 years 99.8%
≥65 years 99.1%
TQS NPV (1-Seroprevalence)×TQS specificity/(((1-Seroprevalence)×TQS
specificity ) + (Seroprevalence×(1-TQS sensitivity)))
18 to 64 years 15.3%
≥65 years 49.1%
TIG relative risk on tetanus occurrence 0 Institut de veille
sanitaire expert
assumption
Tetanus vaccine relative risk on tetanus
occurrence
1 Institut de veille
sanitaire expert
assumption
Pr hospitalization│tetanus case 100% [23-26]
Pr death│tetanus case
<70 years 10.0% 0% 100.0% [23-26]
≥70 years 27.2% 0% 42.0% [23-26]
Pr sequelae│surviving tetanus case 31.6% 18.8% 50.0% [23-26]
c TQS (€ 2012) € 4.7 € 4 € 5 [9,17]
c tetanus vaccine (Revaxis®: 0.5 mL syringe)
(€ 2012)
€ 10.0 € 3 € 15 [27]
c human TIG (Gammatetanos®: 250 IU/2 mL
syringe) (€ 2012)
€ 34,9 € 30 € 40 [27]
c hospitalization tetanus case (€ 2012) € 209,000 € 150,000 € 250,000 [28]
c sequelae of a tetanus case (€ 2012) € 5,663 € 5,000 € 6,000 [28]
Pr: probability; c: cost; │: among (in case of a conditional probabilities); ED: Emergency Department; TQS: Tétanos Quick Stick; TIG: Tetanus immunoglobulins;
PPV: Positive predictive value; NPV: Negative predictive value; GP: General practitioner.
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rates were calculated by age group and type of wound
based on national observational data between 2000 and
2011 (see Additional file 1: Technical Appendix).
Specific tetanus incidence rates obtained were: for pa-
tients between 18–64 years, 0.3 and 1.6 cases per million
for non-tetanus-prone and tetanus-prone wounds re-
spectively; and 8.8 and 41 cases per million for patients
aged ≥65 years (see Additional file 1: Technical appen-
dix). In patients in whom tetanus occurred, we consid-
ered that the probability of being hospitalized was 1.
Mortality and the probability of long-term sequelae were
estimated using data on the surveillance of tetanus from
the French Institut de Veille Sanitaire [23-26].
Costs
The estimated cost of the TQS was €4.7 according to
Lesimple et al. [9]. No TQS administration cost was con-
sidered, assuming that costs associated with the workingtime spent performing the test would be roughly equal to
the time needed to conduct the medical interview. Treat-
ment costs included tetravalent booster vaccine (Revaxis®,
Sanofi Pasteur MSD: €10) and TIG (Gammatetanos®,
Laboratoire LFB Biomédicaments: €34.9) and were ob-
tained from the Vidal (French equivalent of the Physicians’
Desk Reference), an online database of information on
healthcare products [27]. The cost of a tetanus case
was estimated using national hospitalization statistics
(= €209,000) [28]. Costs related to tetanus sequelae were
assessed by taking into account stays in the follow-up
care and rehabilitation departments also using national
hospitalization statistics and were estimated as €5,390 [28].
Outpatient costs related to tetanus cases were not
included since in this analysis in this analysis since they
were considered to be negligible when compared to
hospitalization costs. In cost calculations, we adopted a
societal perspective. We only included direct and differ-
ential medical costs between the strategies compared
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ance (in 2012 euros). The tetanus incidence is very low
in France and the study perspective was fixed at one year
[1]. Consequently, productivity cost were considered as
negligible and not included. Since the study does not
include human material or human data, because only
published data from a literature review were used, the
approval of an ethics committee was not needed.Sensitivity analysis
In addition to a sub-analysis based on the nature of the
wound (tetanus-prone or not) and the patient’s age, one-
way sensitivity analyses were performed for all probabil-
ities and costs, to evaluate the robustness of our results
and to explore the impact that parameter uncertainties.
In those analyses, we used estimates for input variables
found in the medical literature but not used in the base
case analysis. When input variables were only from one
study, a plausible range of values was built based on as-
sumptions. For the parameters identified in the one-way
sensitivity analysis as having a high impact on results, a
threshold analysis was performed to determine at which
values outside plausible ranges the choice of optimal
strategy could be changed. We also considered and ex-
plored several scenarios in our sensitivity analysis. We
considered cases where a monovalent vaccine or equine
immunoglobulins were administered (see Additional file 1:
Technical Appendix).Table 3 Effectiveness and cost of tetanus immunity diagnosti
Cohort Strategies Tetanus
case
Effectivenes
(LY)
All wounded patients Medical Interview 0.41 58,658,086.40
N =1,658,000 TQS 0.02 58,658,087.40
ΔC −0.39 1
Patients with a Medical Interview 0.13 40,494,923.00
Non-tetanus-prone wound TQS 0.01 40,494,923.30
N =1,145,000 Δ −0.13 0.3
Patients with a Medical Interview 0.28 18,163,163.40
Tetanus-prone-wound TQS 0.02 18,163,164.10
N =513,000 Δ −0.26 0.7
Patients 18–64 years Medical Interview 0.04 56,180,160.90
N =1,383,000 TQS 0 56,180,161.00
Δ −0.04 0.10
Patients of 65 Medical Interview 0.37 2,477,925.50
Years and over TQS 0.02 2,477,926.40
N =275,000 Δ −0.35 0.9
ED: Emergency departments; LY: Life years; LYG: Life Years Gained; TQS: Tétanos Qu
aOnly wounded patients over 18 years coming in 2012.
bThe number of tetanus cases with each strategy was low and comparable; differen
consider that the current analysis is a cost-minimization rather than a cost-effective
cΔ = Defined as the delta of the transition from the “Medical Interview” strategy toResults
Under current practice, our model predicted approxi-
mately one tetanus case per year among those who sought
medical care in the ED for a wound. This correlated well
with the observed number of tetanus cases per year in
France caused by wound infection and that would have
led to an ED consultation [23-26].
Base-case analysis
In the present context, for 1,658,000 patients presenting
at the ED with wounds, the use of the “TQS” strategy
resulted in 0.02 tetanus cases per year compared with
0.41 cases per year for “Medical Interview” (Table 3).
The number of tetanus cases with each strategy was thus
low and comparable. We will therefore only focus on
costs and consider that the current analysis is a cost-
minimization rather than a cost-effectiveness analysis.
The overall “TQS” strategy was less costly than “Medical
Interview”: €19,361,000 compared with €21,564,000. In-
creased costs incurred by TQS use (€6,866,000) were offset
by reduction of unnecessary prophylaxis (€8,988,000): 42%
decreases in booster shots and TIG doses. The average cost
per patient was: €13 with “Medical Interview” vs. €11.7
with “TQS” for the overall cohort.
Sub-analysis results
The two sub-groups where the TQS use generated
the greatest savings were the tetanus-prone wounds
(€3,939,000) and the 18–64 years old patients (€1,956,000).c strategies in wounded patients in French EDa,b
s Vaccine
dose
TIG
dose
TQS
cost
Prophylaxis
cost
Total
cost
1,033,000 320,000 - € 21,478,000 € 21,564,000
601,000 186,000 € 6,866,000 € 12,490,000 € 19,361,000
−432,000 −134,000 € 6,866,000 -€ 8,988,000 -€ 2,203,000
713,000 - - € 7,118,000 € 7,145,000
415,000 - € 4,740,000 € 4,139,000 € 8,881,000
−298,000 - € 4,740,000 -€ 2,979,000 € 1,736,000
320,000 320,000 - € 14,360,000 € 14,419,000
186,000 186,000 € 2,126,000 € 8,351,000 € 10,480,000
−134,000 −134,000 € 2,126,000 -€ 6,009,000 -€ 3 939,000
838,000 260,000 € 17,048,000 € 17,438,000
469,000 145,000 € 5,726,000 € 9,755,000 € 15,482,000
−369,000 −115,000 € 5,726,000 -€ 7,293,000 -€ 1,956,000
195,000 60,000 - € 4,430,000 € 4,126,000
132,000 41,000 € 1,140,000 € 2,735,000 € 3,879,000
−63,000 −19,000 € 1,140,000 -€ 1,695,000 -€ 247,000
ick Sticks; TIG: Human tetanus immunoglobulins; N: Cohort size.
ces in effectiveness was negligible. We therefore only focus on costs and
ness analysis.
the “TQS” strategy.
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overall costs, but to a lesser extent (€247,000). However,
for the non-tetanus-prone wounds cohort, the “TQS”
strategy cost more than “Medical Interview” while being
more effective. The transition from current practice to the
“TQS” strategy however cost €5,292,000/life years gained
(LYG). The average cost per patient with “Medical Inter-
view” vs. “TQS” was: €6.2” vs. €7.8 for non-tetanus-prone
wounds; €28.9 vs. €21 for tetanus-prone wounds; €126.1
vs. €112 for patients between 18–64 years of age and €15
vs. €14.1 for patients aged ≥65 years.Sensitivity analysis
One way
A one-way sensitivity analysis on cost and effectiveness
was performed for each variable across their range of
plausible values shown in Table 2. Figure 2 shows the
parameters values for which the model was most sensi-
tive to the global costs of the strategies’ global costs.
The proportion of tetanus-prone wounds in the cohort
and TQS sensitivity were the parameters whose vari-
ation led to the highest change in costs, but without
inversion of the preferred strategy. Indeed, a decrease in
prophylaxis costs could change the base-case conclu-
sion. For a vaccine cost below €4.9 (vs. €10 in the base
case), and a TIG cost below €18.5 (vs. € 34.9 in the base
case), “TQS” was no longer cost-saving compared with
current practice.Threshold analysis
Results of the threshold analysis showed that for a TQS
sensitivity under 61.2% (vs. 69% in the base case), or a
TQS cost over €6.2 (vs. €4.7 in the base case), the TQS cost
was no longer cost-saving compared with the “Medical
Interview” strategy.Figure 2 Tornado analysis on strategy incremental costs: incremental c
strategy (in 2012 Million euros). TQS: Tétanos Quick Stick; TIG: Human tetanAlternative scenarios
When we considered that patients were treated with
equine TIG (which cost €4.1 vs. €34.9 for the human
TIG in the base case), “TQS” was no longer cost-saving
and was associated with an ICER of 875,000 €/LYG.
Similar results were observed when we explored the case
where a monovalent vaccine was administered (€2.82 vs.
€10 for the tetravalent vaccine used in the base case)
with an ICER of 1,887,000€/LYG (Additional file 1:
Technical Appendix). In every other scenarios and sensi-
tivity analysis performed where the “TQS” cost was
higher than “Medical Interview”, it never appeared to be
cost-effective.
Discussion
We found that in adult patients presenting to the ED
with wounds, for comparable effectiveness “TQS” was
less expensive than a strategy based on medical inter-
view. The difference in costs was mainly due to the
decrease in unnecessary tetanus prophylaxis achieved
because of the higher sensitivity of TQS in identifying
protected patients who do not need prophylaxis. Sub-
analyses showed that the “TQS” strategy is especially
cost-saving in patients with tetanus-prone wounds, where
costly TIG injections are recommended, and for patients
with a low tetanus seroprevalence (the elderly). However
the TQS cost was higher than current practice for non-
tetanus prone wounds or when lower prophylaxis costs
were explored; and in those cases TQS was associated
with high ICER. This was due to the fact the number of
cases adverted compared to current practice was always
negligible due to low tetanus incidence rates. Therefore,
the very small gap in effectiveness between the strategies
lead to extremely high ICERs that were never considered
cost-effective in the French context (>3 × French GPD =
€90,000).ost of the “TQS” strategy compared with the “Medical Interview”
us immunoglobulins.
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other countries, this study is to our knowledge the first
model-based study to evaluate the cost-effectiveness of
the TQS in France. This study design allows us to simu-
late the impact of TQS use as well as several alternative
scenarios of wound management. Results on effectiveness
obtained with our model converge to those reported by
French institutions (<1 case of tetanus per year among pa-
tients who present to the ED vs. 0.45 in our model for the
“Medical Interview” strategy). This illustrates the internal
validity of our results.
Our results are consistent with previous epidemio-
logical studies. For example, Hatamabadi et al. found the
use of TQS in Tehran, Iran, to be cost-saving for emer-
gency patients with tetanus-prone wounds (average cost
per patient €12.1 with “Medical Interview” vs. €9.5 with
“TQS”), but not for patients with non-tetanus-prone
wounds (€0.1 with “Medical Interview” vs. €4 with the
“TQS”) [7]. In an assessment of test efficiency in five
hospitals in three regions of Belgium (Brussels, Flanders
and Wallonia), Stubbe et al. found that TQS use was
cost-saving for tetanus-prone wounds for all age groups
(€10.6/patient with the “TQS” vs. €11.3 with “Medical
Interview”) [14]. However, they found that TQS use did
not lead to cost-saving for non-tetanus-prone wounds
(€7.3/patient with the “TQS” vs. €3.9/patient with “Medical
Interview”) [14].
Our results were sensitive to prophylaxis costs. For ex-
ample, for a TIG cost under €18.5 or vaccine cost under
€4.9, the “Medical Interview” strategy became less ex-
pensive than “TQS”. These values are above the cost of
equine TIG and of monovalent vaccine, which suggests
that TQS use would not be cost-saving if tetanus
prophylaxis was solely based on those components. Vari-
ation of TQS sensitivity and cost could also change the
results. However, their threshold values were outside
plausible ranges found in the literature, and very far from
values considered in our base case analysis, which were
conservative when considering the “Medical Interview”
strategy. This illustrates the robustness of our results.
Our study has several limitations. First, our results are
valid for the specific French ED setting, wound care man-
agement and costs. However, given that wound manage-
ment is quite comparable, at least in other European
countries, our results can probably be extrapolated to
other settings. Second, data used for the model came from
various studies and some may not represent the French
context. However, model inputs were varied over a wide
range and our results were robust to these variations.
Third, for reasons of feasibility and data availability, only
two wound categories were considered. The third category
of wounds in French clinical guidelines for tetanus
prophylaxis was not considered (Table 1). We included
this category (which seems to represent only 4.9% of alltypes of wounds observed in EDs [6]) in the “tetanus-
prone wound” category. Because patients with this third
type of wound must receive two TIG injections, this could
have resulted in underestimation of the number of TIG
injections prescribed in our model. Consequently, this
might have led to underestimation of the reduction of
prophylaxis costs generated by use of TQS, which further
strengthens our results. The same would have been
observed if primary vaccination follow-up had been
considered; indeed, due to the higher specificity of the
TQS, fewer patients incorrectly identified as not having
received primary vaccination would have been sent to the
general practitioner.
Although the impact of those tests have been evaluated
in high income countries, their use could be highly rele-
vant in poorer countries with a higher tetanus incidence
due to a lack of tetanus immunity in wounded patients..
In such settings, TQS use could minimize tetanus prophy-
laxis costs, but more importantly maximize effectiveness
in terms of life years gained, due to its high specificity in
the detection of unprotected patients.
Conclusions
In conclusion, in patients seeking care for a wound in
French EDs, TQS use is cost-saving compared with the
“Medical Interview” strategy. The TQS is especially cost-
saving in patients with tetanus-prone wounds, and to a
lesser extent in patients aged ≥65 years. Therefore, its use
should be specifically recommended in this population.
Additional file
Additional file 1: Technical Appendix. We assessed the effectiveness
and cost of TQS use in French emergency departments (EDs) in patients
seeking care for a wound, compared with the medical interview regarding
vaccination history. We developed a decision-tree model that retraces
clinical practice in the ED and includes screening for immunity to tetanus in
wounded patients, conditional prophylaxis administration, and risk of
tetanus occurrence. Data used as input in the model were found through
an extensive literature review. In the Technical Appendix we describe in
detail the sources of the probabilities and costs selected as parameters. We
explain the methods and provide the formula used to estimate the cohort
life expectancy and the patient’s tetanus immunity and its identification by
the two diagnostic methods compared. We also report in detail how we built
incidence rates in non-protected patients who were incorrectly diagnosed,
according to their age and type of wound. Finally, we present additional
results of the sensitivity analyses conducted as part of this study.
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